J. Gordon Foulkes, Ph.D.

President and Chief Executive Officer, Excaliard Pharmaceuticals Inc.

Dr. J. Gordon Foulkes has more than 25 years of experience in biopharmaceutical research and development. Gordon served as the founding CEO of Excaliard from 2007-2009, and has now resumed that role. Gordon headed R&D, and served on the board of multiple biotechnology companies, including Oncogene Science, Inc. (OSI pharma was acquired by Takeda in 2010), Aurora Biosciences (acquired by Vertex in 2001), and Elitra Pharmaceuticals (acquired by Merck). At OSI, he pioneered the early development of cell-based high-throughput drug screening and oversaw multiple drug discovery and development programs. In his operating roles, Gordon had a lead role in securing more than 15 corporate partnerships, resulting in over $200 million in recognized collaborative revenues. He has also directly participated in raising over $160 million in private, IPO, and follow-on public offerings. Prior to re-joining Excaliard, he served as a Managing Director at RiverVest Ventures, representing the fund in Mpex (acquired by Axcan), CGI Pharmaceuticals (acquired by Gilead), Cabrellis (acquired by Pharmion), Conforma (acquired by Biogen), MacroGenics and Excaliard. Prior to joining Industry, Dr. Foulkes held academic positions at both MIT and the MRC (UK).

Nicholas M. Dean, Ph.D.

Founder and Chief Scientific Officer

Prior to founding Excaliard in the spring of 2006, Dr. Dean served for four years as Vice President of Functional Genomics and Oncology at Isis Pharmaceuticals where he also served as Managing Director, Isis Singapore. Dr. Dean originally joined Isis Pharmaceuticals in 1991 and served in various roles in the molecular pharmacology department until 2000 at which time he became Executive Director and Vice President, Functional Genomics for Isis Pharmaceuticals. Dr. Dean received his Ph.D. in Pharmacology from the Welsh National School of Medicine. He then spent time conducting research at the National Cancer Institute and the University of Hawaii before joining Isis Pharmaceuticals. Dr Dean has authored more than 110 scientific papers, and more than 50 issued patents.

Alana McNulty

Chief Financial Officer

Ms. Alana B. McNulty joined Excaliard in 2011, having spent over twenty years working with biotechnology companies in various senior finance, business development and operating roles. Ms. McNulty has led or played a key role in raising more than $500 million through various private and public financings, corporate partnerships and debt financing transactions. Most recently, Alana was the Vice President of Finance and Acting CFO for BrainCells Inc. (2004-2011). Previously, she served in various Executive positions including the CFO and VP of Finance of Elitra Pharmaceuticals (1998 to 2002), the General Manager of the cartilage joint venture between Advanced Tissue Sciences (ATS) and Smith & Nephew, as well as the Executive Director of Corporate Development at ATS (1991-1998). Ms. McNulty holds a MBA from the Anderson School of Management at the University of California, Los Angeles and a bachelors degree in Biological Sciences from the University of California, Santa Barbara.

Jeff Jensen

Vice President, Clinical Operations

Jeff Jensen brings to Excaliard over 25 years of clinical operations experience and has successfully overseen the outsourcing of hundreds of clinical trials. Prior to joining Excaliard, he was Senior Director of Clinical Operations at Metabasis Therapeutics and a Director of Study Management and Development Operations at Pfizer. In addition, Mr. Jensen has held senior level positions at some of the industry's top clinical research organizations. He was Vice-President of Operations at INC Research, a leading CNS and oncology CRO, Chief Operating Officer for Therapeutic Management, and Director of Clinical Operations at Quintiles. Before joining INC Research he gained international experience as Director of Clinical Research in Europe at Pharmaco LSR (currently PPD). Mr. Jensen earned a Bachelor of Science degree in Biochemistry and Biophysics at Oregon State University.

Gary Gentzkow, M.D.

Chief Medical Officer

Dr. Gentzkow is an Internal Medicine physician with a 30+ year career entirely devoted to developing new medical therapies—pharmaceutical, biological & cellular, and medical devices. For the past 20 years, Dr. Gentzkow has focused on wound healing and other skin-related research, particularly using celluar therapies, including engineered human tissues, a field in which he has lectured and published extensively.

Earlier in his career, at Abbott Laboratories, American Critical Care, 3M Pharmaceuticals and Synergen, he directed the clinical development programs for several classes of pharmaceuticals: antiarrhythmics, cardiovascular, critical care, pulmonary, antiinfective, antiinflammatory, muscle relaxant/analgesic products, growth factors and electrical stimulation for wound healing. From 1992-2006 at Advanced Tissue Sciences and Smith & Nephew, Dr. Gentzkow headed the clinical research programs for the engineered human tissues, Dermagraft® and TransCyte®, FDA-approved for diabetic foot ulcers and burns respectively. He has also directed clinical aspects of research programs on cartilage, blood vessels, and cardiovascular regeneration. He has published numerous articles and presented extensively around the world in the field of wound healing and cardiovascular medicine.

During his career he has had primary responsibility for the clinical development and market introduction of several drugs and biologics that have achieved FDA approval including Bretylol (bretylium tosylate),Tamobocr (flecainide acetate), IV dopamine, IV nitroglycerin, Dermagraft®, TransCyte®, Nouricel™, and human collagen.

Dr. Gentzkow received his A.B. degree cum laude from Harvard University and earned his M.D. degree from the University of Oregon Health Sciences Center.

Elizabeth Gordon, Ph.D.

Head of Regulatory Affairs and Project Management

Dr. Elizabeth Gordon is a recognized expert in regulatory affairs with 18 years experience in the pharmaceutical industry and at the FDA. Dr. Gordon has an in-depth understanding of the requirements for successful new drug registration along with a first-hand appreciation for facilitating interactions with the FDA.

In addition to her position as Head of Regulatory Affairs and Project Management at Excaliard Pharmaceuticals, Dr. Gordon is President of EG Consulting, Inc., where she provides expert regulatory advice on requirements for biological and pharmaceutical product development.

Dr. Gordon also served as Senior Director, Regulatory Affairs, in the Medical and Regulatory Services Division of Quintiles Transnational, where she assisted clients in the development of efficient worldwide product development programs and provided strategic regulatory advice on all aspects of therapeutic development from discovery through post-marketing. She also assisted clients with communications with regulatory agencies and the preparation of all regulatory filings.

Prior to Quintiles, Dr. Gordon spent 6 years at the Food and Drug Administration serving as Special Assistant to the Director, Office of Vaccines Research and Review, and Acting Associate Director for Regulatory Policy, Office of Therapeutics Research and Review in the Center for Biologics Evaluation and Research (CBER). She also served as a reviewer of INDs and BLAs for numerous biological products, and was a reviewing microbiologist in the Division of Anti-Infective Drug Products in the Center for Drug Evaluation and Research. At CBER, she was instrumental in developing policy for the regulation of biological products. Dr. Gordon also coordinated numerous sessions of advisory committee meetings for CBER.

Dr. Gordon has a Ph.D. in Microbiology from the University of Rhode Island and received a B.A. in Microbiology from the University of New Hampshire. She also completed an Executive M.S. in Technology Management at the University of Maryland.